Gossamer Bio (GOSS) vs iBio (IBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Gossamer Bio (GOSS) over the past year, gaining 5.7% versus a loss of 94.9%. Over five years, GOSS leads with a -99.1% price change compared with -99.8% for IBIO. Gossamer Bio is the larger company by market cap ($61.6 million vs $60.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | IBIO |
|---|---|---|
| Share price | $10.08 | $0.947 |
| Market cap | $61.62M | $60.90M |
| 1-day change | +1.97% | +2.94% |
| YTD return | -96.02% | -52.33% |
| 1-year return | -94.90% | +5.75% |
| 5-year return | -99.12% | -99.80% |
| EPS (TTM) | $-52.80 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $309.60 | $3.82 |
| 52-week low | $9.12 | $0.78 |
| Distance from 52-week high | -96.75% | -75.21% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +718.66% | +500.84% |
| Average volume | 378.37K | 727.93K |
| Shares outstanding | 6.12M | 64.31M |
| Employees | 161 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed GOSS by 100.6 percentage points over the past year.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
GOSS vs IBIO FAQ
Which is bigger, Gossamer Bio or iBio?
Gossamer Bio (GOSS) is larger, with a market capitalization of $61.62M compared with $60.90M for iBio (IBIO).
Which stock has performed better over the past year, GOSS or IBIO?
IBIO returned +5.75% over the past 12 months, compared with -94.90% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and iBio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.